On Thursday, Shares of AT&T, Inc. (NYSE:T), lost -0.43% to $34.80.
AT&T, Digital Life ®, a home security and automation service, and Habitat for Humanity are ongoing their partnership to rebuild and revitalize communities around the U.S. This effort will kick off in Los Angeles on Thursday, May 28, with local AT&T employee volunteers assisting build a Habitat home in partnership with a low-income family. AT&T Digital Life is planning to support local builds in five cities across the country counting: Los Angeles, Dallas, Atlanta, Miami and Newark. These builds will take place throughout the month of June as AT&T Digital Life continues to give back and support local communities.
Digital Life, which offers home security and automation services to customers, continues efforts with Habitat for Humanity to assist bring people together to build homes, communities and hope. To amplify these efforts, AT&T will donate $150,000 to support Habitat for Humanity’s mission.
AT&T Inc. provides telecommunications services in the United States and internationally. The company operates through two segments, Wireless and Wireline. The Wireless segment offers data and voice services, counting local, long-distance, and network access services, in addition to roaming services to youth, family, professionals, small businesses, government, and business customers.
Shares of XOMA Corporation (NASDAQ:XOMA), inclined 7.83% to $3.58, during its last trading session.
XOMA Corporation, declared that the gevokizumab Phase 3 EYEGUARD-B study, sponsored by its development partner Servier, reached its target exacerbation event as specified in the study design. The objective of the first part of this study is to demonstrate the superiority of gevokizumab, as contrast to placebo, on top of the current standard of care (immunosuppressant therapy and oral corticosteroids) in reducing the risk of Behcet’s disease uveitis exacerbations and to assess the safety of gevokizumab.
Servier now will start the process of closing the clinical database and analyzing the data from this part of the study. Servier has offered a detailed plan of the activities it will undertake to allow the locking of the database. The primary endpoint result is predictable in about seven weeks. The trial is ongoing and remains double-masked for the extension period of the study.
The Phase 3 EYEGUARD-B study (A randomisEd, double-masked, placebo-controlled studY of the Efficacy of GevokizUmAb in the tReatment of patients with Behcet’s Disease uveitis) was designed to enroll patients with a history of Behcet’s disease uveitis with ocular involvement of the posterior segment who have practiced a recent ocular exacerbation that was treated successfully with high doses of corticosteroids. Patients were randomized to either a 60 mg dose of gevokizumab or placebo administered subcutaneously once monthly on top of their current immunosuppressive and corticosteroid therapies. The primary endpoint is the time to first acute ocular exacerbation.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
At the end of Thursday’s trade, Shares of Cypress Semiconductor Corporation (NASDAQ:CY), lost -0.14% to $13.95.
Integrated Silicon Solution, Inc. (ISSI) offered an update on its discussions regarding the unsolicited offer from Cypress Semiconductor Corporation, proposing to acquire all of the outstanding common stock of ISSI for $19.75 per share in cash and on the status of the pending acquisition of ISSI by Uphill Investment Co. for $19.25 per share in cash following the Agreement and Plan of Merger dated as of March 12, 2015.
As formerly declared, upon receiving the Cypress offer, the ISSI Board of Directors determined in good faith, after consultation with ISSI’s financial advisor and outside legal counsel, that the Cypress offer either constitutes or is reasonably predictable to lead to a Superior Proposal (as defined in the Uphill Agreement), and that the failure to take part or engage in talk aboutions or negotiations with Cypress and/or furnish information to Cypress would reasonably be predictable to be inconsistent with its fiduciary duties to the company stockholders under Delaware Law.
Cypress Semiconductor Corporation provides mixed-signal programmable solutions, semiconductor memories, and integrated semiconductor solutions worldwide. The company’s Memory Products division designs and manufactures static random access memory (SRAM) products and nonvolatile RAMs used to store and retrieve data in networking, wireless infrastructure and handsets, computation, consumer, automotive, industrial, and other electronic systems; and general-purpose programmable clocks.
Finally, Activision Blizzard, Inc. (NASDAQ:ATVI), ended its last trade with 0.06% gain, and closed at $25.73, hitting its highest level.
Prepare for a globetrotting Call of Duty® DLC experience like no other, against the backdrops of several of the greatest monuments around the world in Call of Duty®: Advanced Warfare Supremacy. On June 2, the third DLC pack for Call of Duty: Advanced Warfare from Activision Publishing, Inc., a wholly owned partner of Activision Blizzard (Nasdaq:ATVI), and Sledgehammer Games, will be accessible first on the Xbox Live online entertainment network for Xbox One and Xbox 360 games and entertainment system from Microsoft, with other platforms to follow.
From the famed steps of Parliament in London, to the snowy confines of the Kremlin in Moscow, players will experience a diverse landscape of multiplayer mayhem, counting the return of one of the most iconic multiplayer maps in Call of Duty history, “Highrise,” which first debuted in 2009’s Call of Duty®: Modern Warfare® 2, now transported to the year 2054.
Activision Blizzard, Inc. develops and publishes online, personal computer (PC), video game console, handheld, mobile, and tablet games worldwide. The company develops and publishes interactive entertainment software products through retail channels or digital downloads; and downloadable content to a range of gamers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
